Pharmaceutical company Daiichi Sankyo Company Limited (DSKYF.PK) Friday said first-quarter profit attributable to owners of the company climbed to 34.9 billion yen from 21.6 billion yen in the comparable quarter last year. Operating profit was 49.1 ... RTTNews.com, 1 month ago
Release date- 31072015 - Tokyo, Japan - Daiichi Sankyo Company, Limited today announced a revision as follows to the 'Results Briefing (Results for Q1 FY2015)' materials originally disclosed at 1:00pm on Thursday , July 31, 2015 . Revised item ...4 Traders, 1 month ago Daiichi Sankyo acquires Ranbaxy in $4.6B deal FierceBiotech, 1 month ago Daiichi Sankyo Announces Details of Executive Share Options PharmiWeb, 1 month ago DAIICHI SANKYO : Announces Details of Executive Share Options 4 Traders, 1 month ago
Digest of Daiichi Sankyo Company, LTD. v. Michelle K. Lee, Director, United States Patent and Trademark Office, No. 2014-1280 (Fed. Cir. July 2, 2015) (precedential). On appeal from D.D.C. Before Moore, Reyna , and Taranto. Procedural Posture : ...Lexology, 1 month ago
Pieris to Get 7th Milestone Payment from Daiichi Sankyo Collaboration to Develop Anticalin Therapeutics [Professional Services Close - Up]
Pieris Pharmaceuticals recently reported it will receive its third milestone payment for the second program in its discovery and development collaboration with Daiichi Sankyo Company, Limited, and seventh milestone payment overall under the multi ...Pharmacy Choice, 1 month ago Pieris Pharmaceuticals Announces Closing of Over-Allotment Option in Public Offering of Common Stock Fat Pitch Financials, 1 month ago Pieris Pharmaceuticals to Host Second Quarter 2015 Investor Call on August 13th Sys-Con Canada, 1 month ago Pieris Pharmaceuticals Reports Financial Results for the Second Quarter Ended June 30, 2015 Sys-Con Media, 3 weeks ago
Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences.
PRWeb Continuing Education Company (CEC) and Daiichi Sankyo Inc have awarded independent educational grants in support of an interaction simulation session entitled "NOACS: What the Evidence Shows in Managing AFib, Stroke Prevention and DVT/PE." ...Industrial Info Financials, 1 month ago PCI in ACS: Deciding Among Clopidogrel, Prasugrel, or Ticagrelor Orthopedics Today, 1 month ago
Release date- 01072015 - Tokyo, Japan - Daiichi Sankyo Company, Limited today announced that its affiliated foundation, the Daiichi Sankyo Foundation of Life Science* (headquarters, Tokyo ; Chairman, Joji Nakayama ) has awarded its 13th Takamine ...4 Traders, 2 months ago 13th Takamine Memorial Daiichi Sankyo Prize Winner Announced Pharmacy Times, 2 months ago
- Fifty-two percent of patients achieved a partial response and 30 percent of patients had stable disease following treatment with PLX3397, an investigational CSF-1R inhibitor - A rare tumor of the joint or tendon sheath, TGCT can lead to ...BioSpace, 1 month ago Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients Vision Monday, 1 month ago
Daiichi Sankyo Release: Recommends Once-daily LIXIANA (edoxaban) For The Treatment And Prevention Of Recurrent Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) In Adults
/PRNewswire/ -- NICE Final Appraisal Determination recommends that edoxaban is a cost effective use of NHS resources The National Institute for Health and Care Excellence (NICE) has recommended a new treatment to help patients ...BioSpace, 1 month ago U.K. Agency Recommends Edoxaban for Deep Vein Thrombosis, Pulmonary Embolism Diagnostic & Invasive Cardiology, 3 weeks ago NICE recommends once-daily LIXIANA for preventing stroke and systemic embolism GM Journal, 4 weeks ago NICE recommends new treatment for blood clots GM Journal, 1 month ago
More from: , Yahoo! Canada...and 1 other sources
With tightening transparency requirements the pharmaceutical industry is under increasing pressure to ensure fully compliant communication and interactions through all areas of their business functions. How can you evolve current business practices ...News-Medical.Net, 1 month ago
Daiichi Sankyo Release: New Therapy To Help Heart Rhythm Patients Means Doctors Are "Spoilt For Choice" 7/10/2015
/PRNewswire/ -- Launch comes as new patients' survey reveals a significant proportion still not receiving adequate treatment for atrial fibrillation, the commonest heart rhythm disorder A new blood-thinning drug therapy to help ...ClinicSpace, 1 month ago
on your WebpageAdd Widget >Get your members hooked!